产品
编 号：F284042
分子式：C12H12N4O3
分子量：260.25
分子式：C12H12N4O3
分子量：260.25
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 22994-85-0
产品详情
生物活性：
Benznidazole (Ro 07-1051) is an antiparasitic medication, with an IC50 of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease.
体内研究：
Benznidazole (100 mg/kg/day, p.o., 30 days) produces a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart, inmice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 isolate and treated at 180 days post infection (p.i.) (i.e. chronic phase) with Benznidazole.Animal Model:Mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12
Dosage:100 mg/kg/day
Administration:Orally for 30 days
Result:Produced a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart.
Benznidazole (Ro 07-1051) is an antiparasitic medication, with an IC50 of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease.
体内研究：
Benznidazole (100 mg/kg/day, p.o., 30 days) produces a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart, inmice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 isolate and treated at 180 days post infection (p.i.) (i.e. chronic phase) with Benznidazole.Animal Model:Mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12
Dosage:100 mg/kg/day
Administration:Orally for 30 days
Result:Produced a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备